|
Oct 26, 2021
|
BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
|
|
|
Oct 20, 2021
|
BioCryst to Report Third Quarter 2021 Financial Results on November 3
|
|
|
Oct 04, 2021
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Sep 21, 2021
|
BioCryst to Present at 2021 Cantor Virtual Healthcare Conference
|
|
|
Sep 20, 2021
|
BioCryst Appoints Dr. Amy McKee to Board of Directors
|
|
|
Sep 15, 2021
|
NICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent Attacks in HAE Patients in the UK
|
|
|
Sep 09, 2021
|
BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates
|
|
|
Sep 03, 2021
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
Sep 02, 2021
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Sep 01, 2021
|
U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst for Delivery to Strategic National Stockpile
|
|
